C-reactive protein as a prognostic factor for mortality in pneumonia patients with liver cirrhosis

Hepato-Gastroenterology

Volumn 61, Issue 133, 2014, Pages 1331-1338

  Lee, Ji Yeon ^a   Lee, Jeong Hoon ^b   Kim, Deog Kyeom ^c   Yim, Jae Joon ^b   Yoo, Chul Gyu ^b   Chung, Hee Soon ^c   Kim, Young Whan ^b   Han, Sung Koo ^b   Lee, Chang Hoon ^b  

^a National Medical Center   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Acute Phase reaction; C reactive protein; Liver cirrhosis; Mortality; Pneumonia; Prognosis

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; BIOLOGICAL MARKER;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD PUGH SCORE; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; HOSPITAL ADMISSION; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; TERTIARY CARE CENTER; AGED; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMMUNITY ACQUIRED INFECTION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PNEUMONIA; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; TIME;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS;

EID: 84906976611     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12548     Document Type: Article

References (38)

1. File TM: Community-acquired pneumonia. Lancet 2003;362:1991-2001.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al.: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72. (Pubitemid 46290553)
3. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, et al.: Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-8. (Pubitemid 28489008)
4. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al.: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. (Pubitemid 27044625)
5. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al.: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. (Pubitemid 36560938)
6. Ananda-Rajah MR, Charles PG, Melvani S, Burrell LL, Johnson PD, Grayson ML: Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis 2008;40:293-300. (Pubitemid 351447991)
7. Izumi S, Hughes RD, Langley PG, Pernambuco JR, Williams R: Extent of the acute phase response in fulminant hepatic failure. Gut 1994;35:982-6. (Pubitemid 24202731)
8. Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, et al.: Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008;63:447-52. (Pubitemid 351692355)
9. Chalmers JD, Singanayagam A, Hill AT: C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219-25. (Pubitemid 351317927)
10. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P: Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 2011;37:1439-46.
11. Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monden M, et al.: Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 1992;111:201-9.
12. Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12. (Pubitemid 38057722)
13. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-7. (Pubitemid 23127332)
14. Le Moine O, Deviere J, Devaster JM, Crusiaux A, Durand F, Bernuau J, et al.: Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. J Hepatol 1994;20:819-24. (Pubitemid 24216896)
15. Bota DP, Van Nuffelen M, Zakariah AN, Vincent JL: Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med 2005;146:347-51. (Pubitemid 41712021)
16. Park WB, Kang CI, Kim DM, Lee KD, Jang HC, Kim HB, et al.: Influence of Liver Dysfunction on the Production of C-Reactive Protein in Liver Cirrhosis Patients with Escherichia coli Bacteremia. Infect Chemother 2003;35:283-8.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
18. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al.: A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70. (Pubitemid 32119037)
19. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994;15:74-80. (Pubitemid 24049800)
20. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP: New insights into the biology of the acute phase response. J Clin Immunol 1999;19:203-14. (Pubitemid 29409449)
21. Tilg H, Dinarello CA, Mier JW: IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997;18:428-32. (Pubitemid 27381984)
22. Hassner A, Kletter Y, Shlag D, Yedvab M, Aronson M, Shibolet S: Impaired monocyte function in liver cirrhosis. Br Med J (Clin Res Ed) 1981;282:1262-3. (Pubitemid 11156860)
23. Berenyi MR, Straus B, Cruz D: In vitro and in vivo studies of cellular immunity in alcoholic cirrhosis. Am J Dig Dis 1974;19:199-205.
24. Thomas HC: The immune response in hepatic cirrhosis: animal and human studies. Proc R Soc Med 1977;70:521-5.
25. Almirall J, Bolibar I, Toran P, Pera G, Boquet X, Balanzo X, et al.: Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004;125:1335-42. (Pubitemid 38501347)
26. Hansson LO, Hedlund JU, Ortqvist AB: Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest 1997;57:111-8. (Pubitemid 27242809)
27. Ortqvist A, Hedlund J, Wretlind B, Carlstrom A, Kalin M: Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995;27:457-62.
28. Coelho L, Povoa P, Almeida E, Fernandes A, Mealha R, Moreira P, et al.: Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007;11:R92.
29. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH: C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995;108:1288-91.
30. Grutzmeier S, Sandstrom E: C-reactive protein levels in HIV complicated by opportunistic infections and infections with common bacterial pathogens. Scand J Infect Dis 1999;31:229-34. (Pubitemid 29389228)
31. Stolz D, Stulz A, Muller B, Gratwohl A, Tamm M: BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest 2007;132:504-14. (Pubitemid 47287555)
32. Agusti C, Rano A, Rovira M, Filella X, Benito N, Moreno A, et al.: Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients. Thorax 2004;59:1081-8. (Pubitemid 39573929)
33. McCracken M, Olsen M, Chen MS, Jr., Jemal A, Thun M, Cokkinides V, et al.: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007;57:190-205. (Pubitemid 47312080)
34. Kallio R, Surcel HM, Bloigu A, Syrjala H: C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 2000;36:889-94. (Pubitemid 30214139)
35. Penel N, Fournier C, Clisant S, N'Guyen M: Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer 2004;12:593-8. (Pubitemid 39062551)
36. Engel A, Mack E, Kern P, Kern WV: An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection 1998;26:213-21. (Pubitemid 28388878)
37. Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U: Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000;111:1093-102. (Pubitemid 32104921)
38. Penel N, Fournier C, Degardin M, Kouto H, N'Guyen M: (Fever and solid tumor: diagnostic value of procalcitonin and C-reactive protein). Rev Med Interne 2001;22:706-14. (Pubitemid 32756540)